Chronic gastricitis is a common stomach disease with more complex causes, in which the infection of the fungus (Hp) is an important factor. Antibacterial treatment has become a key link for patients who are positive for cholesterocococcal chronic gastroenteritis, with the aim of eradicating cholesterosomiasis, improving stomach inflammation and preventing disease progression and related complications.
First, the relationship between cholesterocella and chronic stomach inflammation. Through its spiral structure, it can easily drill through the mucous layer of the gastric mucous membrane, attached to the upper skin of the stomach, causing chronic inflammation of the gastric mucous membrane through a variety of virulent factors, such as urea enzymes, vacoxin A (VacA), cytoxin-related genes A (CagaA). Long-term cholesterocococcal infections can lead to repeated damage to and repair of the gastric mucous membranes, causing gradual atrophy of the gastric mucous membranes, intestinal changes, and increasing the risk of stomach cancer. According to studies, about 60% – 70% of chronic stomach inflammation patients are infected with cholesterol.
Secondly, antibacterial treatment adapts not all chronic stomach disease patients need antibacterial treatment. In general, the following are recommended for treatment for the eradication of cholesterol: 2. Symptoms of indigestion, such as stomach pain, stomach swelling, anti-acid, gaseous, etc., and confirmed as a result of cholesterosomiasis. 3. Family history of stomach cancer. 4. Planned long-term use of inflammatory drugs (NSAIDs) or those already in use. 5. Reduction in the incidence of ulterior diseases, such as vitriol, associated with cholesterococcal infections.
Currently, the clinically commonly used antibacterial treatment programme for the eradication of cholesterol is a four-pronged treatment of proton pump inhibitor (PPI), americium and antibiotics. Proton pump inhibitors: The most common drugs are Omera, Lansola, Rebella and Pitola. The mechanism of action is to inhibit gastric acidization, increase PH values in the stomach and create an enabling acidic environment for antibiotics to function, with some direct antibacterial activity. The general dose is the standard dose, two times a day and half an hour before the meal. Americium: potassium acetate is commonly used. The acetate, acting with gastric acid, forms abalone salt and viscous condensation, covering the surface of the gastric mucous membranes, which, on the one hand, can protect the gastric mucous membranes from further effects of gastric acids and cholesterol, on the other hand, can directly inhibit the growth of cholesterol. The dose was 220 mg per dose, two times a day, half an hour before the meal. Antibiotics: Two types of antibiotics are often selected, such as Amocrin, Cracin, Metrazine, Furane. The most commonly used doses in Amosilin are 1000 mg per day, 2 times per day, 500 mg per caracin, 2 times per day, 400 mg per day, and 100 mg per day, 2 times per day. The choice of antibiotics should be considered in the light of the patient ‘ s individual circumstances, his or her history of allergies, and his or her local antibiotic resistance. For example, in some parts of the country, where resistance rates are high for Kracino and Metrazine, and relatively low for Amocrin and Furanone, priority is given to a combination of drugs with low resistance rates to increase eradication rates. A standard QT session is usually 10 – 14 days. For example, Omera 20 mg + potassium acetate 220 mg + Amosilin 1000 mg + kracin 500 mg, 2 sessions per day, 14 days of treatment.
1. Patient dependence: explain to the patient in detail the importance and necessity of the treatment programme, emphasizing the importance of timely and proportionate drug use in order to ensure good patient compliance. Irregular drug use is one of the common causes of treatment failure. 2. Adverse effects monitoring: A number of adverse effects may occur in the course of treatment, such as gastrointestinal reaction (e.g., nausea, vomiting, diarrhoea), rashes, dizziness, e.g., americ acid can lead to black poop, black tongue, constipation, etc., and proton pump inhibitors may have headaches, abdominal pain, diarrhoea etc. Patients should be informed of possible adverse reactions and should continue to be observed if the symptoms are minor, and should be referred to the medical adjustment programme in a timely manner if the symptoms are serious. 3. Drug interaction: Certain drugs may interact with drugs in treatment programmes, affect therapeutic efficacy or increase the risk of adverse reactions. Proton pump inhibitors, for example, may affect the metabolism of certain anti-facter drugs, anti-condensation drugs, etc. Before treatment, patients should be asked about their drug history in detail, avoiding drug interaction. Post-treatment review: Once the treatment has been completed, a review will normally take place four weeks after the detoxification, using a carbon-13 or carbon-14 exhalation test to test the eradication of the cholesterocella. The review may lead to a false negative result too early, as the cholesterol may be temporarily suppressed and not completely removed after treatment.
Efficacy assessment and follow-up management for antibacterial treatment If the results of the review indicate that the treatment is successful, it shows that the fungus coli is negative. At this point, it is possible to decide whether to continue treatment of the symptoms or to follow up regularly to observe the recovery of gastric mucous disease, depending on the patient ‘ s symptoms. If the results of the review are still positive, the reasons for the failure of treatment, such as the patient ‘ s lack of adherence, antibiotic resistance, insufficient dosage of the drug or inadequate treatment process, need to be analysed, and the treatment programme adjusted to the specific circumstances of the case for eradication. The type of antibiotics, the extension of treatment or other remedial treatment can generally be replaced. 2. Follow-up management: For those who have succeeded in eradicating cholesterol, dietary hygiene is still required to avoid re-infection. At the same time, for patients suffering from pathologies such as carving of gastric mucous membranes, intestinal organisms and so forth, a regular gastroscope examination should be conducted to monitor the progress of the pathologies in order to detect early detection and timely treatment of stomach cancer or pre-cancer pathologies. The antibacterial treatment of chronic stomach disease is a systematic and complex process that requires a comprehensive consideration of the individual circumstances of the patient, a rigorous certificate of adaptation, a rational choice of treatment, and a focus on the various components of the treatment process, in order to increase the eradication rate of cholesterosomiasis and improve the patient ‘ s prognosis and reduce the risk of chronic stomach disease-related complications.
